Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial.

By S. Yokota, T. Imagawa, M. Mori, T. Miyamae, Y. Aihara, S. Takei, N. Iwata, H. Umebayashi, T. Murata, M. Miyoshi and 3 more. The Lancet, 2008

738 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

IL-6 in inflammation, immunity, and disease. (2014, background): “…100 countries (Tanaka et al. 2013), Cite this article as Cold Spring Harb Perspect Biol 2014;6:a016295 9 as well as for systemic and polyarticular juvenile idiopathic arthritis (Yokota et al. 2008, 2012; De Benedetti et al. 2012) and Castleman’s disease (Nishimoto et al. 2005) in several countries.”
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. (2014, background): “Tocilizumab is the first FDA approved drug for SJIA, which affects children primarily by causing joint destruction (Yokota et al., 2008).”
Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. (2011, background): “Interestingly, a phase III trial in patients with rheumatoid arthritis failing anti–TNF-α therapy showed that certain individuals display increased responsiveness to tocilizumab (120, 121).”
The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease (2020, background): “The apparent recognition of MAS/sHLH complicating COVID-19 pneumonia forms the backdrop for cytokine suppression strategies [6, [22] [23] [24] , although the evidence for these cytokines being effective for active MAS complicating sJIA itself is not compelling [25] .”
Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. (2012, neutral): “Rash 24/41 (59) 20/43 (47) 4/43 (9) 79/177 (45) 1/100 (1) 3/50 (6) 9/50 (18)”